ACH logo

ACCENDRA HEALTH INC

ACHNYSE
πŸ† #4463 by market capUS Equity
$286.36β–Ό $4.81 (βˆ’1.68%)
Simulated price
πŸ””
Track ACH
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.7%
7dβ–² 33287.0%
14dβ–² 25241.6%
30dβ–² 23372.1%
ytdβ–² 10145.4%
1yβ–² 6018.8%
🏦Market Cap
$50M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-69.7%
Declining
πŸ“ŠGross Margin
44.8%
Healthy
πŸ’΅FCF Margin
2.2%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
52
Weak

Trading Snapshot

Day Range
$284.62 – $289.55
52-Week Range
$0.66 – $5.60
Volume
$3.84B
Avg Volume
$2.60B
Shares Outstanding
76.6M
Next Earnings
Nov 24, 2026

Fundamentals Snapshot

Annual Revenue
$2.76B
Last Q Revenue
$613M
P/E Ratio
β€”
P/S Ratio
0.0x
EPS (TTM)
$-3.93
Dividend Yield
β€”
Dilution (1yr)
βˆ’0.6%

Why Investors Own ACH

  • βœ“High-growth profile β€” revenue up -0.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 28% gross margin and 21% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ACH logo

ACCENDRA HEALTH INC

ACH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.8Bβ–Ό βˆ’74.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
46.7%β–² +125.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$222Mβ–Ό βˆ’206.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$303Mβ–² +354.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
76.7Mβ–Ό βˆ’0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2.0Bβ–² +$139M YoY
StockOtter Β· stockotter.space

About ACCENDRA HEALTH INC

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
52/100

Analyst Price Target

β“˜
Average Target
$376.26
β–² +31.4% Upside
High Target$408.84
Low Target$335.75
Based on 16 analysts

Latest News & Updates